Prorenin stimulates a pro-angiogenic and pro-inflammatory response in retinal endothelial cells and an M1 phenotype in retinal microglia

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 5, 2015, Pages 537-548

  Zhu, Tong ^a   Miller, Antonia G ^a   Deliyanti, Devy ^a   Berka, David R ^a   Agrotis, Alex ^a   Campbell, Duncan J ^b   Wilkinson Berka, Jennifer L ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Endothelial cells; Inflammation; Microglia; Prorenin; Retinopathy

Indexed keywords

ALISKIREN; ANGIOPOIETIN 1; ARGINASE 1; CANDESARTAN; EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PRORENIN; PRORENIN RECEPTOR; PROTEIN TYROSINE KINASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CELL SURFACE RECEPTOR; RENIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; MICROGLIA; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; RETINA CELL; WESTERN BLOTTING; ANGIOGENESIS; ANIMAL; BOVINE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; INFLAMMATION; METABOLISM; PATHOLOGY; RAT; RETINA; SPRAGUE DAWLEY RAT;

ANIMALS; CATTLE; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; INFLAMMATION; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; RENIN; RETINA;

EID: 84928185258     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12376     Document Type: Article

References (44)

1. Wilkinson-Berka JL, Agrotis A, Deliyanti D. The retinal renin-angiotensin system: Roles of angiotensin II and aldosterone. Peptides 2012; 36: 142-50.
2. Sarlos S, Wilkinson-Berka JL. The renin-angiotensin system and the developing retinal vasculature. Invest. Ophthalmol. Vis. Sci. 2005; 46: 1069-77.
3. Kurihara T, Ozawa Y, Nagai N et al. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 2008; 57: 2191-8.
4. Moravski CJ, Kelly DJ, Cooper ME et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000; 36: 1099-104.
5. Moravski CJ, Skinner SL, Stubbs AJ et al. The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: Transgenic and interventional studies. Am. J. Pathol. 2003; 162: 151-60.
6. Phipps JA, Wilkinson-Berka JL, Fletcher EL. Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Invest. Ophthalmol. Vis. Sci. 2007; 48: 927-34.
7. Chaturvedi N, Porta M, Klein R et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomised, placebo-controlled trials. Lancet 2008; 372: 1394-402.
8. Sjolie AK, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomised placebo-controlled trial. Lancet 2008; 372: 1385-93.
9. Danser AH, van den Dorpel MA, Deinum J et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J. Clin. Endocrinol. Metab. 1989; 68: 160-7.
10. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N. Engl. J. Med. 1985; 312: 1412-7.
11. Yokota H, Nagaoka T, Mori F et al. Prorenin levels in retinopathy of prematurity. Am. J. Ophthalmol. 2007; 143: 531-3.
12. Campbell DJ. Critical review of prorenin and (pro)renin receptor research. Hypertension 2008; 51: 1259-64.
13. Wilkinson-Berka JL, Heine R, Tan G et al. RILLKKMPSV influences the vasculature, neurons and glia, and (pro)renin receptor expression in the retina. Hypertension 2010; 55: 1454-60.
14. Deliyanti D, Miller AG, Tan G, Binger KJ, Samson AL, Wilkinson-Berka JL. Neovascularization is attenuated with aldosterone synthase inhibition in rats with retinopathy. Hypertension 2012; 59: 607-13.
15. Satofuka S, Ichihara A, Nagai N et al. (Pro)renin receptor promotes choroidal neovascularization by activating its signal transduction and tissue renin-angiotensin system. Am. J. Pathol. 2008; 173: 1911-8.
16. Satofuka S, Ichihara A, Nagai N et al. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 2007; 48: 422-9.
17. Satofuka S, Ichihara A, Nagai N et al. Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest. Ophthalmol. Vis. Sci. 2006; 47: 2686-92.
18. Muller DN, Klanke B, Feldt S et al. (Pro)renin receptor peptide inhibitor 'handle-region' peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension 2008; 51: 676-81.
19. Batenburg WW, van den Heuvel M, van Esch JH et al. The (pro)renin receptor blocker handle region peptide upregulates endothelium-derived contractile factors in aliskiren-treated diabetic transgenic (mREN2)27 rats. J. Hypertens. 2013; 31: 292-302.
20. Sapieha P, Hamel D, Shao Z et al. Proliferative retinopathies: Angiogenesis that blinds. Int. J. Biochem. Cell Biol. 2010; 42: 5-12.
21. Joussen AM, Poulaki V, Le ML et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004; 18: 1450-2.
22. Marchetti V, Yanes O, Aguilar E et al. Differential macrophage polarization promotes tissue remodeling and repair in a model of ischemic retinopathy. Sci. Rep. 2011; 1: 76.
23. McCarthy CA, Widdop RE, Deliyanti D, Wilkinson-Berka JL. Brain and retinal microglia in health and disease: An unrecognized target of the renin-angiotensin system. Clin. Exp. Pharmacol. Physiol. 2013; 40: 571-9.
24. Saris JJ, van den Eijnden MM, Lamers JM, Saxena PR, Schalekamp MA, Danser AH. Prorenin-induced myocyte proliferation: No role for intracellular angiotensin II. Hypertension 2002; 39: 573-7.
25. Feldt S, Maschke U, Dechend R, Luft FC, Muller DN. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J. Am. Soc. Nephrol. 2008; 19: 743-8.
26. Butash KA, Natarajan P, Young A, Fox DK. Reexamination of the effect of endotoxin on cell proliferation and transfection efficiency. Biotechniques 2000; 29: 610-9.
27. Sakoda M, Ichihara A, Kaneshiro Y et al. (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens. Res. 2007; 30: 1139-46.
28. Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ. Res. 1998; 82: 619-28.
29. Kanda A, Noda K, Saito W, Ishida S. (Pro)renin receptor is associated with angiogenic activity in proliferative diabetic retinopathy. Diabetologia 2012; 55: 3104-13.
30. Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl Acad. Sci. USA 1995; 92: 10 457-61.
31. Uraoka M, Ikeda K, Nakagawa Y et al. Prorenin induces ERK activation in endothelial cells to enhance neovascularization independently of the renin-angiotensin system. Biochem. Biophys. Res. Commun. 2009; 390: 1202-7.
32. Ferri N, Greco CM, Maiocchi G, Corsini A. Aliskiren reduces prorenin receptor expression and activity in cultured human aortic smooth muscle cells. J. Renin Angiotensin Aldosterone Syst. 2011; 12: 469-74.
33. Nagai N, Noda K, Urano T et al. Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest. Ophthalmol. Vis. Sci. 2005; 46: 1078-84.
34. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. 2013; 328: 18-26.
35. Felcht M, Luck R, Schering A et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J. Clin. Invest. 2012; 122: 1991-2005.
36. Yoshida S, Yoshida A, Ishibasi T, Elner SG, Elner VM. Role of MCP-1 and MIP-1alpha in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization. J. Leukocyte Biol. 2003; 73: 137-44.
37. Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog. Retin. Eye Res. 2010; 29: 284-311.
38. Checchin D, Sennlaub F, Levavasseur E, Leduc M, Chemtob S. Potential role of microglia in retinal blood vessel formation. Invest. Ophthalmol. Vis. Sci. 2006; 47: 3595-602.
39. Kataoka K, Nishiguchi KM, Kaneko H, van Rooijen N, Kachi S, Terasaki H. The roles of vitreal macrophages and circulating leukocytes in retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 2011; 52: 1431-8.
40. Fischer F, Martin G, Agostini HT. Activation of retinal microglia rather than microglial cell density correlates with retinal neovascularization in the mouse model of oxygen-induced retinopathy. J. Neuroinflammation 2011; 8: 120.
41. Zubcevic J, Jun JY, Lamont G et al. Nucleus of the solitary tract (pro)renin receptor-mediated antihypertensive effect involves nuclear factor-kB-cytokine signaling in the spontaneously hypertensive rat. Hypertension 2013; 61: 622-7.
42. Campbell DJ, Nussberger J, Stowasser M et al. Activity assays and immunoassays for plasma renin and prorenin: Information provided and precautions necessary for accurate measurement. Clin. Chem. 2009; 55: 867-77.
43. Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ. Res. 2009; 104: 124-33.
44. Wilkinson-Berka JL, Deliyanti D, Rana I et al. NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. Antioxid. Redox Signal. 2014; 20: 2726-40.